These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine. Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197 [TBL] [Abstract][Full Text] [Related]
5. EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease. Vorobyov VV; Schibaev NV; Morelli M; Carta AR Brain Res; 2003 May; 972(1-2):177-85. PubMed ID: 12711091 [TBL] [Abstract][Full Text] [Related]
7. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Kemmerer ES; Desmond TJ; Albin RL; Kilbourn MR; Frey KA Exp Neurol; 2003 Sep; 183(1):81-6. PubMed ID: 12957491 [TBL] [Abstract][Full Text] [Related]
8. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Sindhu KM; Saravanan KS; Mohanakumar KP Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782 [TBL] [Abstract][Full Text] [Related]
9. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. McGrath J; Lintz E; Hoffer BJ; Gerhardt GA; Quintero EM; Granholm AC Cell Transplant; 2002; 11(3):215-27. PubMed ID: 12075987 [TBL] [Abstract][Full Text] [Related]
10. The 6-OHDA mouse model of Parkinson's disease - Terminal striatal lesions provide a superior measure of neuronal loss and replacement than median forebrain bundle lesions. Bagga V; Dunnett SB; Fricker RA Behav Brain Res; 2015 Jul; 288():107-17. PubMed ID: 25841616 [TBL] [Abstract][Full Text] [Related]
11. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease. Howells FM; Russell VA; Mabandla MV; Kellaway LA Behav Brain Res; 2005 Dec; 165(2):210-20. PubMed ID: 16159673 [TBL] [Abstract][Full Text] [Related]
12. CART modulates the effects of levodopa in rat model of Parkinson's disease. Upadhya MA; Shelkar GP; Subhedar NK; Kokare DM Behav Brain Res; 2016 Mar; 301():262-72. PubMed ID: 26771081 [TBL] [Abstract][Full Text] [Related]
13. Priming of rotational behavior by a dopamine receptor agonist in Hemiparkinsonian rats: movement-dependent induction. Simola N; Di Chiara G; Daniels WM; Schallert T; Morelli M Neuroscience; 2009 Feb; 158(4):1625-31. PubMed ID: 19063947 [TBL] [Abstract][Full Text] [Related]
14. Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity. Van Kampen JM; McGeer EG; Stoessl AJ Synapse; 2000 Sep; 37(3):171-8. PubMed ID: 10881039 [TBL] [Abstract][Full Text] [Related]
15. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617 [TBL] [Abstract][Full Text] [Related]
16. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats. Pollack AE; Yates TM Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212 [TBL] [Abstract][Full Text] [Related]
17. Dopamine, Noradrenaline and Serotonin Receptor Densities in the Striatum of Hemiparkinsonian Rats following Botulinum Neurotoxin-A Injection. Mann T; Zilles K; Dikow H; Hellfritsch A; Cremer M; Piel M; Rösch F; Hawlitschka A; Schmitt O; Wree A Neuroscience; 2018 Mar; 374():187-204. PubMed ID: 29421436 [TBL] [Abstract][Full Text] [Related]
18. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422 [TBL] [Abstract][Full Text] [Related]
19. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons. Chen L; Zhang QJ; Liu J; Wang S; Ali U; Gui ZH; Wang Y Brain Res; 2009 Aug; 1286():192-200. PubMed ID: 19545547 [TBL] [Abstract][Full Text] [Related]
20. Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6-hydroxydopamine-lesioned rats. Pollack AE; Turgeon SM; Fink JS Neuroscience; 1997 Jul; 79(1):79-93. PubMed ID: 9178866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]